Therapeutic RSK1 Targeting in Myelofibrosis

计划入组 18 人 · 首次发布于 2026 年 1 月 30 日

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

计划入组 61 人 · 首次发布于 2019 年 10 月 4 日

Comparison of Intubation Duration Between Rapid Sequence Intubation (RSI) Technique and Non-RSI Technique

计划入组 224 人 · 首次发布于 2011 年 11 月 18 日

RSK2 CDx

Streptokinase

Rx

AAV-RBD gene therapy (Anchored Rsk3 Inhibitors)

RKS PHARMACEUTICAL, INC.

United States

RSV Therapeutics LLC

RPK Pharmaceuticals, Inc.

United States

RSK1 Inhibitor PMD-026 Shows Promise in Treating Blood Cancers in Addition to Breast Cancer

Phoenix Molecular Designs Initiates Phase 2 Trial of PMD-026 Combination Therapy for Advanced Breast Cancer

Aptose and NCI Partner to Advance Tuspetinib in AML and MDS Trials